RB Goldberg, VA Fonseca, KE Truitt, MR … - Archives of internal …, 2008 - archinte.highwire.org Methods A prospective, 16-week, multicenter, randomized, double-blind, placebo-controlled,
parallel-group study conducted at 50 sites in the United States and 1 site in Mexico between
August 12, 2004, and December 28, 2005. Subjects had type 2 diabetes mellitus that was ... Cited by 18 - Related articles - All 5 versions
KL Edwards, C Alvarez, BK Irons, J Fields - Pharmacotherapy, 2008 - PPI Patients with type 2 diabetes mellitus often begin treatment by taking oral agents, usually metformin
or a sulfonylurea, and then progress to the combination of these two agents. Most patients often
require three or more agents or a change to an insulin regimen. However, no guidelines ... Cited by 3 - Related articles - BL Direct - All 3 versions
M Dorkhan, A Frid, L Groop - Diabetes Research and Clinical Practice, 2008 - Elsevier Thirty-six patients inadequately controlled on metformin and sulfonylurea/meglitinide were randomized
to receive add-on therapy with insulin glargine or pioglitazone for 26 weeks. Insulin was up-titrated
to achieve fasting plasma glucose <6 mmol/l. Pioglitazone was increased to 45 mg/day ... Cited by 2 - Related articles - All 23 versions
R Clissold, S Clissold - Core Evidence, 2007 - dovepress.com Effective glycemic control in type 2 diabetes Clear IG was at least as effective as NPH
insulin, other insulin regimens, and rosiglitazone or pioglitazone Lower incidence of hypoglycemia
in type 2 diabetes Clear Significantly less hypoglycemia with IG than with NPH insulin Cited by 1 - Related articles - View as HTML - BL Direct - All 3 versions
J Seufert - Fundamental & Clinical Pharmacology, 2009 - interscience.wiley.com The complex array of metabolic abnormalities associated with type 2 diabetes provides a number
of new targets for therapeutic intervention. Although the established oral glucose-lowering
therapies, metformin and the sulfonylureas, continue to provide the backbone of ... Related articles - All 2 versions
JM Gamble, SH Simpson, LC Brown, JA Johnson - Open Medicine, 2008 - openmedicine.ca Data sources: We searched the following electronic databases from inception until June
2007: MEDLINE; EMBASE; Cochrane Central Register of Controlled Trials; Web of Science;
Scopus; CINAHL; International Pharmaceutical Abstracts; Academic OneFile; PASCAL; ... Related articles - Cached - All 2 versions
JM Gamble, SH Simpson, LC Brown, JA Johnson - Open Medicine, 2008 - openmedicine.ca Insulin versus an oral antidiabetic agent as add-on ... JM Gamble, Scot H. Simpson, Lauren
C. Brown, Jeffrey A. Johnson ... Background: Although evidence-based guidelines for the treatment
of type 2 diabetes mellitus provide clear recommenda- tions for initial therapy, evidence ... Related articles - View as HTML - All 2 versions
MB Davidson - Current Opinion in Endocrinology, Diabetes and …, 2009 - journals.lww.com Introduction There is an increasing chorus of people recommending insulin as 'early' treatment
of type 2 diabetes in both print [1 ] and at national meetings [2]. A subtext of this recommendation
is to use insulin as the initial treatment for newly diagnosed patients with type 2 diabetes. ... Related articles - All 5 versions